What is malaria, and why is it a medical emergency?
Malaria is a potentially fatal parasitic disease caused by protozoa of the genus Plasmodium, transmitted to humans through the bite of infected female Anopheles mosquitoes. It is the deadliest parasitic disease in the world (600,000 deaths per year, WHO 2022), affecting mainly sub-Saharan Africa, but also tropical areas of Asia and Latin America. Any fever occurring within 3 months of returning from an endemic area constitutes a medical emergency requiring diagnosis. Check out our mosquito repellents, mosquito sprays, and mosquito-repellent bracelets.
- The 5 human Plasmodium species: P. falciparum —the most severe and widespread form (sub-Saharan Africa)—causes severe malaria with complications—increasing resistance to treatments — P. vivax — the second leading cause worldwide (Asia, Latin America) — can remain dormant in the liver (hypnozoites) → possible relapses after recovery — P. ovale (Africa) — P. malariae (chronic form) — P. knowlesi (Southeast Asia — zoonosis, potentially severe form)
- Parasitic life cycle: Anopheles bite → sporozoites injected → liver (hepatic schizogony, 7–30 days) → red blood cells (erythrocytic schizogony) → release of merozoites at regular intervals (48 hours for P. vivax and falciparum, 72 hours for P. malariae) → cyclic fever episodes + rupture of red blood cells → anemia
- Symptoms and clinical presentation: incubation period 7–30 days (up to several months for P. vivax) — fever (often in cyclic episodes) + chills + sweating + headaches + muscle aches + nausea — in severe cases: severe anemia + thrombocytopenia + renal failure + cerebral involvement (neuropaludism—altered consciousness, seizures, coma) + pulmonary edema
- Emergency diagnosis: any fever upon return from a tropical area → diagnostic testing within 4 hours — blood smear + thick smear (gold standard — species identification + parasite density) — Antimalarial RDT (rapid test in 15–20 minutes — 90–95% sensitivity for P. falciparum) — PCR (reference test in a specialized laboratory) — never wait for results if clinical syndrome is suggestive → treat on a probabilistic basis if P. falciparum is suspected
- Absolute emergency: P. falciparum malaria → mandatory hospitalization — severe forms (neuropaludism, hemoglobinuria, respiratory distress) → intensive care
Chemoprophylaxis and medication-based prevention for travelers
- Principle of chemoprophylaxis: antimalarial drugs taken before, during, and after travel to an endemic area — reduce the risk of a malaria attack by 80–90% — do not replace vector control measures (The ABCD of prevention: Awareness, Bites, Chemoprophylaxis, Diagnosis) — selection based on geographic area, length of stay, health status, and drug interactions
- Atovaquone-proguanil (Malarone): the standard treatment for most destinations (areas with chloroquine-resistant P. falciparum ) — to be started 1–2 days before departure, continued during the stay, and 7 days after return — well tolerated — contraindicated if creatinine clearance < 30 mL/min — requires a doctor’s prescription
- Mefloquine (Lariam): alternative — start 10 days before departure (tolerance test) — 1 tablet per week during the trip + 3 weeks after return — contraindicated in cases of psychiatric history, epilepsy, or arrhythmias — possible neuropsychiatric effects — a doctor’s prescription is required
- Doxycycline: alternative for Southeast Asia — 100 mg/day from the first day of travel until 4 weeks after return — contraindicated in children under 8 years of age and during pregnancy — photosensitizing (sun protection required) — doctor’s prescription required
- Chloroquine alone (Nivaquine): only for areas without resistance (very rare) — resistance to chloroquine is widespread in most endemic areas — consult the updated recommendations from the CMVI (Committee on Travel-Related and Imported Diseases) — interactive map on pasteur.fr and sante.fr
Vector protection: repellents, mosquito nets, and environmental measures
- Skin repellents: most effective against Anopheles mosquitoes (which bite mainly at night and indoors) — DEET (30–50% for adults, 10–30% for children over 2 years old) — 20% icaridin (IR3535, Picaridin) — apply to exposed skin after sunscreen — reapply every 4–6 hours — check out our mosquito repellent lotions and roll-ons
- Insecticide-treated bed nets (ITNs): pyrethroids (permethrin) — 90% effective against transmission — re-treat the net every 6 months (or choose long-lasting insecticidal nets, LLINs) — sleep under a net even in urban areas (Anopheles mosquitoes may be present in cities)
- Treated, long-sleeved clothing: long-sleeved tops and pants in the evening and at night — treat clothing with permethrin (insecticide) — mosquito repellent sprays for fabrics — provides additional repellent effect
- Air conditioning and window screens:Anopheles mosquitoes primarily bite indoors at night — air conditioning + window screens = an effective barrier — mosquito repellent bracelets (citronella, essential oils): supplemental protection but insufficient on its own against malaria
- Infants and children: special baby mosquito repellents — IR3535 < 10% for infants — treated bed and stroller mosquito nets — avoid high-risk malaria areas with infants if possible
Curative treatment, follow-up, and immune support
- Curative treatment for uncomplicated P. falciparum malaria: artemisinin-based combination therapies (ACT) — artemether-lumefantrine (Riamet/Coartem) — artesunate-amodiaquine — eradication therapy for P. vivax/ovale: primaquine (eliminates hepatic hypnozoites—requires G6PD testing before prescription)—always under medical supervision—prescription required
- Severe malaria: IV artesunate (WHO standard of care) + intensive care — transfer to a specialized unit (infectious diseases or intensive care) — laboratory monitoring every 12–24 hours (parasitemia + complete blood count + creatinine + coagulation)
- Drug resistance: Chloroquine-resistant P. falciparum present in nearly all endemic countries — emerging partial resistance to artemisinin in Southeast Asia and Africa (WHO surveillance) — requires constant adaptation of chemoprophylaxis and treatment recommendations
- Immune support for prevention and recovery: people traveling to endemic areas benefit from optimal antiparasitic immunity— vitamin D3, zinc, selenium, and vitamin C — visit our immune defense page — natural supplements do not protect against malaria and are never a substitute for drug-based chemoprophylaxis
- RTS,S/AS01 (Mosquirix) vaccine: first vaccine approved by the WHO (2021) — 30–55% efficacy against severe malaria episodes in children — vaccination program underway in sub-Saharan Africa — does not protect European travelers — a second vaccine (R21/Matrix-M) showing >70% efficacy is being rolled out
